This finding is important because the authors observed an upregulation of CXCR4 expression in MM cells with increasing bortezomib treatment, and as a consequence, CXCR4/CXCL12 expression decreased the responsiveness of the MM cells to bortezomib. This evidence concerns the gene CXCL12 and Miyoshi myopathy.